Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix
for their prostate cancer, will be followed for a period of one year. In this real-life,
non-interventional trial, any cardiovascular events occurring during degarelix therapy will
be documented.